Source comparison
TB-500 Dose Response Research: Comparison Across Models
Murine myocardial infarction 1.5–12 mg/kg IV bolus Infarct size reduction, ejection fraction Plateau at 6 mg/kg. No added benefit above this threshold Rodent cardiac physiology differs substantially; immune response timelines compressed Porcine wound healing 3
This comparison does not assign a generated winner or score.
- Murine myocardial infarction
- 1.5–12 mg/kg IV bolus
- Infarct size reduction, ejection fraction
- Plateau at 6 mg/kg. No added benefit above this threshold
- Rodent cardiac physiology differs substantially; immune response timelines compressed
- Porcine wound healing
- 3–12 mg/kg subcutaneous over 14 days
- Collagen deposition rate, tensile strength
- Linear response 3–6 mg/kg, plateau 6–12 mg/kg
- Wound environment not replicated in surgical models; confounded by concurrent growth factors
- Equine tendon injury
- 5–20 mg local injection per site
- Ultrasound-verified collagen alignment, lameness score
- Modest benefit at all tested doses; no clear dose-dependency observed
- Single-site injection; systemic effects not measured; recovery timelines extend months beyond observation
- Human observational (case reports)
- 2–5 mg subcutaneous twice weekly
- Subjective recovery reports, MRI findings
- Not dose-controlled; insufficient data for pattern analysis
- No control group; concurrent treatments; retrospective reporting bias
- Professional Assessment
- The dose that saturates actin-binding sites without triggering non-specific immune activation hasn't been identified in humans. Animal models suggest 4–8 mg/kg as a therapeutic ceiling, but translating that to human protocols requires Phase I pharmacokinetic studies that haven't been conducted.